|
The Maine Immunization Program has received additional doses of COVID-19 vaccine for under and uninsured adults 19 years and older. These doses are essentially “supplemental bridge vaccine doses”. While the previous Bridge Access Program (BAP) doses were available in larger quantities, this current batch is capped at 2,500 doses. Out of this total, 2,400 doses are Moderna, and 100 are Novavax.
Providers enrolled with the Maine Immunization Program have the option to order these supplemental COVID-19 doses, along with additional doses that can be ordered through the 317 program. This is an additional option available to providers this year. Any doses ordered through the 317 program will be dependent on the current 317 funding available.
Please email MEAdultVaccine@maine.gov to enroll in our 317 program and to request doses.
We now have several materials available to order for free on our materials order page. These materials are to be used in promotion of the Docket app. Currently available, we have posters, window clings and business cards.
Order now for your office!
To learn more about the Docket app, please visit our website.
This is no longer allowed. This was a one-time allowance using Bridge Access Program (BAP) operations funds for COVID-19 vaccine provided as part of the Bridge program. These funds can be used to pay the admin fee for COVID-19 vaccine administered before the end of the program (prior to August 22). No other COVID operations funding can be used to reimburse providers for the COVID-19 vaccine administration fees for any 2024 – 2025 COVID-19 vaccine.
BAP COVID-19 VACCINE ADMINISTERED PRIOR TO AUGUST 22, 2024:
If you have submitted an invoice to receive reimbursement for administering BAP COVID-19 vaccine prior to the August end date, we will begin processing these over the next several weeks. If you have not yet submitted an invoice, please send your administration information to: MEAdultVaccine@maine.gov.
As part of FDA’s actions, the 2023–2024 Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. To minimize the risk of vaccine administration errors, providers should:
- Remove all 2023–2024 mRNA COVID-19 vaccines from storage units immediately, even if they are not expired.
- Once all inventory is fully accounted for, delete 2023–2024 COVID-19 mRNA vaccine listings from the available vaccine inventory in your Immunization Information System, as applicable.
- Return all unused 2023–2024 mRNA COVID-19 vaccines to CDC’s centralized distributor using the normal process for returning spoiled/expired vaccines.
|
VAERS is the national passive surveillance system for vaccine safety, co-managed by FDA and CDC.
The VAERS form can be filled out by:
- Healthcare providers
- Patients, family members and caregivers
- Manufacturers
- VAERS has a new portal that allows bulk upload for healthcare providers at:
- Available languages: English and Spanish
- More information and electronic form available here.
New feature: V-safe integration with VAERS:
- Participants who report a
medically attended event after
vaccination prompted to
complete a VAERS report after
finishing their V-safe survey.
- Software link to prepopulate fields in VAERS with information already provided to V-safe.
V-safe and VAERS help CDC communicate timely and transparent information about the safety of vaccine. For materials and more information, please visit:
V-safe
VAERS
Starting in May 2024, Pfizer began using a new Packing List with the 12+ COVID-19 "Never Frozen" shipments. As seen in the screenshot below, this packing list contains information listed on it showing the date and time by which the product should be received. If the shipment is not received within the stated time on packing list, there are instructions for the recipient to contact Pfizer Customer Service to determine product viability.
Pfizer Customer Service: 800-666-7248
There are three different pack list options for the 2024-2025 season, depending on where vaccines ship from; providers should be familiar with the following options:
| Option |
Which vaccines? |
|
Two stickers on the inner flap of shipper
|
Any vaccines
|
|
Paper pack list inside shipper
|
Comirnaty (never frozen) 12y+ only
|
|
*NEW* (see pictures below) Underside of
shipping label on the outside of the shipper
|
Any vaccines
|
Shipping label has markings along the sides that indicate “Peel for Pack Slip.”
Through a comprehensive analysis, AIM identified five promising practices for improving the uptake of COVID-19 vaccination and advancing vaccine equity for children ages 6 months to 11 years. This toolkit includes resources that provide answers to the “what,” “why,” and “how” of implementing five promising practices for improving pediatric COVID-19 immunization rates. It also includes examples from the field, partnerships to consider, resources, tools, tips, and lessons learned.
-
Targeted Outreach: Conducting targeted outreach to Medicaid beneficiaries for COVID-19 vaccines by linking immunization information system and Medicaid data
-
Basic Needs: Connecting opportunities to vaccinate children against COVID-19 with the chance to address basic needs of children and families
-
Mobile Clinics: Using mobile clinics to vaccinate children against COVID-19 at community-based locations
-
At-home Vaccination: Vaccinating children against COVID-19 at home
-
Provider Support: Providing operational support to help pediatric health care providers vaccinate children against COVID-19
Explore the toolkit for resources related to the five promising practices here. |
